Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05319093 · ClinicalTrials.gov registry record
Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients
A clinical trial, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- 26
- Enrollment target
NCT05319093 is a clinical trial that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 26 participants.
The verdict
NCT05319093 was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
Multi-center observational study to assess the short-term response of multiple sclerosis (MS) patients initiated on Ozanimod with respect to fatigue. Patterns of brain changes on brain magnetic resonance imaging (MRI) that might modulate the effect of Ozanimod treatment on fatigue will also be assessed.
Interventions
- DRUG Ozanimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2024-07-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05319093
The ClinicalTrials.gov registry entry for NCT05319093 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ozanimod is the first listed.
NCT05319093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05319093 about?
NCT05319093 is a clinical study titled "Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients". Multi-center observational study to assess the short-term response of multiple sclerosis (MS) patients initiated on Ozanimod with respect to fatigue. Patterns of brain changes on brain magnetic resonance imaging (MRI) that might modulate the effect of Ozanimod treatment on fatigue will also be asses...
What is the current status of trial NCT05319093?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 2022-04-01. Estimated completion is 2024-07-23.
What interventions are being tested in trial NCT05319093?
The interventions under investigation include: Ozanimod (DRUG).
Who is sponsoring clinical trial NCT05319093?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.